← FDA DRUG APPROVALS

FDA ANDA · ANDA090540

CLOPIDOGREL

clopidogrel bisulfate

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA090540
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-17
LATEST ACTION
2023-06-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CLOPIDOGREL BISULFATEPrescription
CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET · ORAL

Approval history

2023-06-08Labeling · Supplement 27 · standardAP
2023-06-08Labeling · Supplement 31 · standardAP
2019-09-20Labeling · Supplement 19 · standardAP
2019-04-03Labeling · Supplement 14 · standardAP
2019-04-03Labeling · Supplement 12 · standardAP
2019-04-03Labeling · Supplement 17 · standardAP
2019-04-03Labeling · Supplement 15 · standardAP
2019-04-03Labeling · Supplement 13 · standardAP
2016-05-11Labeling · Supplement 10 · standardAP
2016-05-11Labeling · Supplement 9 · standardAP
2014-06-11Labeling · Supplement 6 · standardAP
2014-06-11Labeling · Supplement 7 · standardAP
2012-05-17OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →